A biomarker analysis of plasma and tumor DNA in afatinib-treated patients with EGFR mutation-positive advanced adenocarcinoma of the lung.
Phase of Trial: Phase II
Latest Information Update: 26 Sep 2018
Price : $35 *
At a glance
- Drugs Afatinib (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- Acronyms Afatinib I I S
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer
- 27 Apr 2018 Status changed from active, no longer recruiting to completed.
- 15 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.